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ABSTRACT
Adipocyte determination and differentiation depen-
dent factor 1 (ADD1)/sterol regulatory element bind-
ing protein isoform (SREBP1c) is a key transcription
factor in fatty acid metabolism and insulin-
dependent gene expression. Although its transcrip-
tional and post-translational regulation has been
extensively studied, its regulation by interacting
proteins is not well understood. To identify cellular
proteins that associate with ADD1/SREBP1c, we
employed the yeast two-hybrid system with an
adipocyte cDNA library. Using the N-terminal
domain of ADD1/SREBP1c as bait, we identi®ed
Twist2 (also known as Dermo-1), a basic helix±loop±
helix (bHLH) protein, as a novel ADD1/SREBP1c
interacting protein. Over-expression of Twist2
strongly repressed the transcriptional activity of
ADD1/SREBP1c, primarily by reducing its binding to
target sequences. Inhibition of histone deacetylase
(HDAC) activity with HDAC inhibitors relieved
this repression. Our data suggest that physical
interaction between Twist2 and ADD1/SREBP1c
attenuates transcriptional activation by ADD1/
SREBP1c by inhibiting its binding to DNA, and that
this inhibition is at least partly dependent on
chromatin modi®cation by HDACs.
INTRODUCTION
Sterol regulatory element binding proteins (SREBPs) play a
critical role in lipid homeostasis by regulating genes involved
in cholesterol and fatty acid metabolism. Three isoforms of
SREBPs have been identi®ed, SREBP1a, SREBP1c (also
known as adipocyte determination and differentiation depen-
dent factor 1 [ADD1]) and SREBP2, constituting a family of
basic helix±loop±helix (bHLH) transcription factors (1±3).
SREBP1a and ADD1/SREBP1c are generated by alternative
promoter usage and alternative splicing from a single gene,
while SREBP2 is encoded by a distinct gene with 47% identity
with SREBP1 (3). Unlike other transcription factors, SREBPs
are inserted into the endoplasmic reticulum (ER) membrane in
a transcriptionally inactive form (4,5). When cellular choles-
terol concentrations are low, SREBP cleavage-activating
protein, together with Insig-1 or Insig-2, escorts SREBPs
from the ER to the Golgi, where they are cleaved in sequence
by Site 1 and Site 2 proteases. The mature forms of SREBPs,
with N-terminal fragments, are then released from the Golgi
and translocate to the nucleus where they bind to the
promoters or enhancers of SREBP target genes (3,5±9).
Of the three SREBPs, it is ADD1/SREBP1c that mainly
activates genes responsible for fatty acid synthesis, including
fatty acid synthase (FAS), lipoprotein lipase (LPL), acetyl
Co A carboxylase (ACC) and steroyl Co A desaturase (SCD)
in fat and liver (3). ADD1/SREBP1c is predominantly
expressed in white adipose tissue, brown adipose tissue and
liver, and its mRNA is induced at an early stage of adipocyte
differentiation (2,10). Ectopic expression of ADD1/SREBP1c
in preadipocyte cell lines promotes adipocyte differentiation
(10) and stimulates the activity of peroxisome proliferator
activated receptor (PPAR) g, a master transcription factor for
adipogenesis, by producing activators (or endogenous ligands)
of PPARg (11). In addition, ADD1/SREBP1c expression is
modulated by nutritional status and regulated in an insulin-
sensitive manner in which it regulates transcription of insulin-
dependent lipogenic genes (12). It is therefore likely that
ADD1/SREBP1c is a major transcription factor coordinating
fatty acid and glucose metabolism in insulin-sensitive organs.
On the contrary, several studies have suggested that ADD1/
SREBP1c is dispensable for the development of adipose tissue
in vivo (13±15). For example, aP2-ADD1/SREBP1c trans-
genic animals show lipodystrophy rather than increased fat
mass (13). However, ADD1/SREBP1c-speci®c knockout
mice have decreased fat mass and severely decreased hepatic
and plasma triglycerides, suggesting that ADD1/SREBP1c is
critical for lipogenesis (14,15).
Compared with other SREBPs, ADD1/SREBP1c is a
relatively weak transcription activator. This can be explained
by the fact that it has few acidic amino acids in its N-terminal
region compared with SREBP1a (16). SREBP1a and SREBP2
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associate through their N-terminal domains with various
transcriptional co-activators including p300, CBP and ARC/
DRIP, but no interaction between ADD1/SREBP1c and co-
activators has been demonstrated (17,18). In addition, it has
been suggested that the transcriptional activity of SREBP1
isoforms is stimulated by interaction with other co-regulatory
factors such as Sp1 and NF-Y (19±21).
Although the transcriptional and post-translational regula-
tion of ADD1/SREBP1c has been investigated intensively,
little is known of proteins that interact with it and regulate its
transcriptional activity. To address this issue, we used the
yeast two-hybrid system. Here we demonstrate that Twist2, a
bHLH protein, is a novel ADD1/SREBP1c interacting protein.
Twist2 (also called Dermo-1) is expressed in fat and liver
where ADD1/SREBP1c is also highly expressed. Over-
expression of Twist2 speci®cally repressed the transcriptional
activity of ADD1/SREBP1c by inhibiting its binding to target
promoters. Furthermore, histone deacetylase (HDAC)-
inhibiting drugs such as sodium butyrate abolished Twist2-
dependent inhibition, implying that Twist2 interferes with
ADD1/SREBP1c in cooperation with HDACs. Together, our
observations suggest that Twist2 antagonizes the transcrip-
tional activity of ADD1/SREBP1c, and that together Twist2
and ADD1/SREBP1c may regulate energy homeostasis.
MATERIALS AND METHODS
Yeast two-hybrid screening
As bait, the N-terminal region of ADD1/SREBP1c containing
the acidic domain (amino acids 1±153) was cloned in-frame
with the Gal4 DNA-binding domain into vector pAS2
(Clonetech). The yeast strain, PJ69-4A, was simultaneously
transformed with the bait plasmid pAS2-Gal4-A153 and a
murine HIB-IB cDNA library, cloned into vector pACT2
according to the manufacturer's instructions (Clonetech).
Positive interactions were tested for lacZ activity and survival
on selective media, and DNA was extracted from positive
clones and sequenced with pACT2-speci®c oligonucleotides.
DNA and protein databases were analyzed with the BLAST
package of search algorithms (http://ncbi.nlm.nih.gov/cgi.bin/
BLAST).
GST pull-down
35S-labeled active forms of ADD1/SREBP-1c and Twist2
were generated with the TNTâ-coupled reticulocyte lysate
system (Promega) under conditions suggested by the manu-
facturer. Each of the in vitro translated proteins (5 ml) was
mixed with 1 mg of recombinant GST±ADD1/SREBP1c
(amino acids 1±403) fusion protein and glutathione±sepharose
beads. Reaction volumes were made up to 150 ml with binding
buffer [10 mM Tris±HCl pH 7.4, 100 mM NaCl, 5 mM EDTA,
0.1% Nonidet P-40 (NP-40) and 1% aprotinin] and incubated
for 2 h at 4°C. As negative control, GST protein was also
added to a mixture with in vitro translated 35S-labeled ADD1/
SREBP-1c or 35S-labeled Twist2. The beads were pelleted,
washed with binding buffer and mixed with SDS-gel sample
buffer (125 mM Tris±HCl pH 6.8, 50% glycerol, 2% SDS, 5%
b-mercaptoethanol and 0.01% Bromophenol Blue). Boiled
samples were subjected to SDS±PAGE and autoradiography.
Plasmid constructs
The FAS-luciferase plasmid containing a ±220 to +25 bp
fragment of the FAS promoter in front of a luciferase reporter
gene was described previously (12). The ADD1/SREBP1c-
luciferase plasmid contains a ±2.7 kb to +1 bp fragment of the
ADD1/SREBP1c promoter in front of a luciferase reporter
gene. Plasmid pRSV-b-gal was used as an internal control.
The active form of the ADD1/SREBP1c expression vector
encoding amino acids 1±403 of rat ADD1, was cloned in-
frame into the pcDNA3.1-Myc/HisA plasmid and pGEX4T-1
vector (Pharmacia). A Twist2 full-length cDNA was cloned
into pRc-CMV vector (Invitrogen). Expression vectors for
HDACs were gifts from Dr Kyu W. Kim. Mature forms of
SREBP1a and SREBP2 cDNAs were cloned into pCMV
plasmid (22).
Cell culture
Murine 3T3-L1 preadipocytes were grown to con¯uence in
Dulbecco's modi®ed Eagle's medium (DMEM) supplemented
with 10% fetal calf serum. At con¯uence (day 0), differen-
tiation of 3T3-L1 cells was induced with DMEM containing
10% FBS, methyl-isobutylxanthine (500 mM), dexamethasone
(1 mM) and insulin (5 mg/ml) for 48 h. The culture medium
was changed every other day with DMEM containing 10%
FBS and 1 mg/ml insulin. The 3T3-F442A cell line was grown
in DMEM and 10% fetal calf serum. Differentiation of the
3T3-F442A cells to adipocytes was induced by addition of the
same medium with 5 mg/ml insulin, and the medium was
changed every other day.
Transient transfections and luciferase assays
H293 cells were transfected 1 day before con¯uence by the
calcium phosphate method described previously (12,23). After
incubation for 24 h, cell extracts were prepared with lysis
buffer (25 mM Tris±phosphate pH 7.8, 2 mM dithiothreitol,
2 mM 1,2-diaminocyclohexane-N,N,N¢,N¢-tetraacetic acid,
10% glycerol, 1% Triton X-100), and activities of b-
galactosidase and luciferase were determined according to the
manufacturer's instructions (Promega). Luciferase activities
were normalized to the corresponding b-galactosidase activi-
ties and/or protein concentration of each lysate. All the
transfection experiments were performed in duplicate and
repeated independently at least three times.
Northern blot analysis
Total RNA was isolated with TRIzol reagent (Invitrogen)
according to the manufacturer's protocol. Twenty micrograms
of each RNA was denatured in formamide and formaldehyde,
and separated by electrophoresis on formaldehyde-containing
agarose gels. It was transferred to nylon membranes
(Schleicher and Schuell, Germany), which were cross-linked,
hybridized and washed as described by the manufacturer.
DNA probes were labeled by random priming using the
Klenow fragment of DNA polymerase I (Promega) and
[a-32P]dCTP (Amersham-Pharmacia). The cDNAs used as
probes were: ADD1/SREBP1c, Twist2, PPARg, b-actin
and aP2.
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The cDNA was synthesized using Moloney leukemia virus
reverse transcriptase with dNTPs and oligo(dT) primers
(Stratagene). The cDNAs provided templates for PCRs using
speci®c primers at annealing temperatures ranging between 54
and 58°C in the presence of dNTPs and Taq DNA polymerase.
PCR synthesis for each primer pair was quanti®ed at 20, 25
and 30 cycles in a test reaction to ensure that the quantitative
PCR ampli®cation was in the linear range. The primer
sequences used for PCR are available upon request.
Electrophoretic mobility shift assay (EMSA)
One microgram of plasmid DNA expressing active ADD1/
SREBP1c or Twist2 was used as template for in vitro
translation. In order to measure translation ef®ciency from
the different plasmid templates, L-[35S]methionine was
included in separate reactions and radio-labeled proteins
were analyzed by SDS±PAGE. The DNA sequences of the
double-stranded oligonucleotides used as probes were as




otides were end-labeled with [g-32P]ATP. T4 polynucleotide
kinase and 0.1 pmol [g-32P]ATP (~30 000 c.p.m.) were used in
20 ml binding reactions containing reaction buffer [10 mM Tris
pH 7.5, 50 mM KCl, 2.5 mM MgCl2, 0.05 mM EDTA, 0.1%
(v/v) Triton X-100, 8.5% (v/v) glycerol, 1 mg of poly (dI±dC),
1 mM dithiothreitol and 0.1% (w/v) non-fat dry milk]. Samples
were loaded onto a non-denaturing 4% polyacrylamide gel.
The gels were dried and autoradiographed.
Chromatin immunoprecipitation assay
Subcon¯uent H293 cells were transiently transfected with
plasmids ADD1/SREBP1c-luciferase, pcDNA-myc/His-
ADD1 (amino acids 1±403) and/or pRC-CMV-Flag-Twist2,
and incubated at 37°C for 48 h. The transfected cells were
cross-linked in 1% formaldehyde at 37°C for 10 min and
resuspended in 200 ml of NP-40-containing buffer (5 mM
PIPES pH 8.0, 85 mM KCl, 0.5% NP-40). Crude nuclei were
precipitated and lysed in 200 ml of lysis buffer (1% SDS,
10 mM EDTA, 50 mM Tris±HCl pH 8.1). Nuclear lysates
were sonicated and diluted 10-fold with IP buffer (16.7 mM
Tris±HCl pH 8.1, 167 mM NaCl, 1.2 mM EDTA, 0.01% SDS,
1.1% Triton X-100). They were then incubated with protein
A±Sepharose CL-4B (Amersham-Pharmacia) and anti-Myc
antibodies for 2 h at 4°C. The immunoprecipitates were
washed for 5 min each with 1 ml of TSE 150 (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris±HCl pH 8.1, 150 mM
NaCl), 1 ml of TSE 500 (0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 20 mM Tris±HCl pH 8.1, 500 mM NaCl), buffer III
(0.25 M LiCl, 1% NP40, 1% deoxycholate, 1 mM EDTA,
10 mM Tris±HCl pH 8.1), and 1 ml of TE (10 mM Tris±HCl at
pH 8.0, 1 mM EDTA). The immune complexes were eluted
with 2 vol of 250 ml elution buffer (1% SDS, 0.1 M NaHCO3),
and 20 ml of 5 M NaCl was added to reverse formaldehyde
cross-linking. DNA was extracted with phenol±chloroform
and precipitated with isopropyl alcohol and 80 mg of glycogen.
The precipitated DNA was ampli®ed by PCR. Conditions for
PCR reactions were: 0.25 mM each primer, 0.1 mM each
dNTP, 13 PCR buffer, 1 U Ex Taq polymerase (TaKaRa,
Japan), 0.06 mCi/ml [a-32P]dCTP in 20 ml reaction volume.
The PCR products were resolved on 8% polyacrylamide/0.53
TBE (Tris±borate±EDTA) gels.
RESULTS
Interaction between Twist2 and ADD1/SREBP1c
To isolate and identify proteins interacting with ADD1/
SREBP1c, the N-terminal region of ADD1/SREBP1c (amino
acids 1±153) was used as bait in the yeast two-hybrid system
together with an adipocyte cDNA library. Twist2 (also known
as Dermo-1), one of several apparently positive clones, was
isolated and shown to bind to ADD1/SREBP1c.
To determine the domain responsible for the interaction, we
generated deletions of ADD1/SREBP1c in-frame with the
DNA-binding domain of Gal4 (Fig. 1A), and examined
interaction between these derivatives and Twist2 by measur-
ing LacZ activities and testing survival on selective medium.
As shown in Figure 1B, when the A60 or A153 bait was
present with Twist2, yeast cells were b-gal positive and
survived on selective medium. In contrast, the proline rich
domain, residues 60±210, or the bHLH domain of ADD1/
SREBP1c, did not have b-gal activity with Twist2. Thus, the
N-terminal region (amino acids 1±60) of ADD1/SREBP1c
appears to be responsible for the interaction with Twist2.
To con®rm the interaction between Twist2 and ADD1/
SREBP1c, we performed a GST pull-down assay. 35S-labeled
Twist2 was incubated with either GST alone or GST±ADD1/
SREBP1c in the presence of glutathione±Sepharose beads.
Since ADD1/SREBP1c forms homodimers, 35S-labeled
ADD1/SREBP1c protein was used as positive control for the
GST pull-down analysis (Fig. 1C, lane 5). As shown in
Figure 1C, 21% of the input full length Twist2 bound to
immobilized GST±ADD1/SREBP1c (lane 6), indicating that
Twist2 forms a stable complex with the N-terminus of ADD1/
SREBP1c in vitro. Twist2 was not detected when GST was
used on its own (Fig. 1C, lane 4).
Expression of Twist2 in liver and adipose tissue
As a key transcription factor for fatty acid metabolism, ADD1/
SREBP1c is highly expressed in fat and liver. To investigate
whether Twist2 is also expressed in tissues where ADD1/
SREBP1c is abundant, we performed northern blot analyses
and semi-quantitative RT±PCR. As shown in Figure 2A,
expression of Twist2 mRNA was detected in both fat and liver
tissue and was also induced during adipocyte differentiation
(Fig. 2B and C). Western blot analysis also showed that
Twist2 is expressed in 3T3-L1 adipocytes, fat tissue and liver
(data not known). These results imply that Twist2 may
modulate the activity of ADD1/SREBP1c in fat and liver
tissue.
Suppression of transcriptional activity of ADD1/
SREBP1c by Twist2
In order to investigate the consequences of the interaction
between ADD1/SREBP1c and Twist2, we examined the tran-
scriptional activity of ADD1/SREBP1c in the presence and
absence of Twist2. Previously, we and others have demonstrated
that the promoters of the FAS and ADD1/SREBP1c genes
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contain binding sites for ADD1/SREBP1c and that they are
transactivated by ectopic expression of ADD1/SREBP1c
(3,12,24). As shown in Figure 3A and B, expression of
ADD1/SREBP1c activated the promoters of FAS and
ADD1/SREBP1c and co-expression of Twist2 suppressed
this activation, while Twist on its own had no effect. This
observation is consistent with recent reports that Twist2 is a
transcriptional repressor of p65 (an NF-kB subunit) and MEF2
(25,26). The proximal promoter region of ADD1/SREBP1c
contains binding sites for LXRa/RXRa as well as ADD1/
SREBP1c and both ADD1/SREBP1c and LXRa/RXRa
independently transactivate ADD1/SREBP1c (24,27,28). As
shown in Figure 3C, co-expression of Twist2 with LXRa/
RXRa did not affect the transcriptional activity of LXRa/
RXRa at the ADD1/SREBP1c promoter, indicating that
Twist2 speci®cally represses the transcriptional activity of
ADD1/SREBP1c. Because SREBP1a and SREBP2 also can
transactivate the FAS promoter, we tested the effect of Twist2
on the transcriptional activity of SREBP1a and SREBP2. As
shown in Figure 3D, while co-expression of Twist2 did not
affect signi®cantly on the transcriptional activity of SREBP2
at the FAS promoter, Twist2 reduced the transcriptional
activity of SREBP1a, whose N-terminal acidic domain
includes almost all amino acid sequences in the acidic region
of ADD1/SREBP1c but for ®ve residues (29).
Twist2 reduces target DNA binding of ADD1/SREBP1c
We tested whether Twist2 interferes with binding of ADD1/
SREBP1c to its target DNA. Unlike other bHLH proteins,
ADD1/SREBP1c has dual DNA-binding speci®city to both
E-boxes (CANNTG) and SRE boxes (ATCACCCCAC),
because it contains an atypical tyrosine residue in place of
the arginine in the basic domain (23). EMSA demonstrated
that Twist2 decreased the DNA-binding ability of ADD1/
SREBP1c at both E-box (Fig. 4A, lanes 3, 8 and 9) and SRE
motifs (Fig. 4B, lanes 3, 7, 8 and 9). Although Twist2 is a
bHLH protein, it did not bind to the SRE or E-box motifs, but
instead interfered with binding by ADD1/SREBP1c by
complexing with it. When Twist2 was reacted with antibody
before mixing with ADD1/SREBP1c, its repressive effect was
relieved (Fig. 4A, lanes 9 versus 10 and B, lanes 9 versus 12).
To establish that Twist2 inhibits DNA binding by ADD1/
SREBP1c in vivo, we performed a chromatin immunopreci-
pitation (ChIP) assay. It has been shown previously that
ADD1/SREBP1c transactivates its own promoter by binding
to the SRE motif (24). When ADD1/SREBP1c protein was
immunoprecipitated in the ChIP assay, DNA fragments
containing the SRE element of the ADD1/SREBP1c promoter
were ampli®ed from the immunoprecipitates (Fig. 5A, lane 3).
Expression of Twist2 with ADD1/SREBP1c inhibited the
binding of ADD1/SREBP1c to its target (Fig. 5A, lane 4).
Western blot analysis showed that the expression levels of
ADD1/SREBP1c and Twist2 were similar (Fig. 5B).
Histone deacetylation is involved in the repression of the
transcriptional activity of ADD1/SREBP1c by Twist2
It has been reported recently, that repression of the transcrip-
tional activity of MEF2 by Twist2 is dependent on HDAC and
that Twist2 forms a complex with E12. We therefore
examined the effects of HDAC inhibitor, sodium butyrate,
on the transcriptional regulation of ADD1/SREBP1c by
Twist2, and found that it prevented Twist2-mediated repres-
sion of the transcriptional activity of ADD1/SREBP1c
(Fig. 6A). In addition, Twist2-dependent repression of the
transcriptional activity of ADD1/SREBP1c was enhanced by
Figure 1. Interaction between Twist2 and ADD1/SREBP1c. (A) Linear
representation of each of the ADD1/SREBP1c constructs with the regions
indicated that were used in the deletion constructs. (B) The Twist2 interact-
ing domain in ADD1/SREBP1c. Each deletion construct was tested for
interaction with full-length Twist2 in the yeast two-hybrid system. cDNAs
encoding amino acids 1±60 (A60, containing the N-terminus acidic domain
which extends from amino acids 1 to 65), amino acids 1±153 (A153),
amino acids 60±210 (A60±210, containing the proline-rich domain from
amino acids 65 to 193.), amino acids 153±308 (A153±308), amino acids
308±403 (A308±403, containing the HLH domain from amino acids 303 to
341) and amino acids 1±403 (A403) of ADD1/SREBP1c, were fused to the
GAL4 DNA binding domain (pAS2), while Twist2 was fused to the tran-
scriptional activation domain (pACT2). Transformants were checked for
interaction by b-gal assay and survival test. Asterisk denotes lacZ activity,
>50% blue colonies in <2 h. A403 bait alone showed strong b-gal activity
(self transcriptional activity, data not shown). (C) GST pull-down assay.
Input of labeled ADD1/SREBP1c (A403) and Twist2 is shown in lanes 1
and 2, respectively. The fraction of labeled proteins that were pulled down
by GST alone, and GST±ADD1/SREBP1c are shown in the later lanes.
Asterisks denote radiolabeled proteins.
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over-expression of HDACs (Fig. 6B). These results imply that
Twist2 contributes to the transcriptional suppression of
ADD1/SREBP1c not only by decreasing the DNA-binding
ability of ADD1/SREBP1c but also by associating with
HDACs.
DISCUSSION
Twist2 is a bHLH protein that was cloned as an E12-binding
partner by yeast two-hybrid screening (30). When hetero-
dimerized with E12, Twist2 binds to E-boxes and Twist-boxes
without displaying any substantial transcriptional activity
(30). Recent studies have revealed that Twist2 represses many
transcription factors. For example, it inhibits MyoD, a
myogenic bHLH transcription factor that is also inhibited by
the Ids family of HLH proteins. Because Id family proteins
have only the HLH domain and not a basic region, they
function as dominant-negative partners of MyoD to inhibit
muscle differentiation (31). Unlike Id proteins, Twist proteins
are able to block DNA binding of MyoD by squelching E12
proteins, which are necessary as partners for ef®cient DNA
binding of MyoD, and bind to MyoD indirectly to form a
transcriptionally inactive complex (25,32,33). Interestingly, it
has been suggested that HDACs are involved in the repression
of MyoD by Twist2 (25). Twist2 is also reported to repress
osteoblast differentiation at the transcriptional level (34±35).
It appears that Twist2 also functions as an oncoprotein,
antagonizing p53-dependent apoptosis (36). Consistent with
this, Twist2 knockout mice show severe growth retardation
and apparently atrophic dermis, thymus, liver and fat tissue,
with increased numbers of apoptotic bodies (26). Loss of
Twist2 results in elevated expression of pro-in¯ammatory
cytokines and perinatal death from cachexia (26). Twist2
mRNA expression is induced by TNFa via the p65 subunit of
NF-kB, and Twist2 appears to repress cytokine gene expres-
sion by a negative feedback loop (26).
We have shown above that Twist2 also regulates ADD1/
SREBP1c by physical interaction. Twist2 was expressed in
Figure 2. Expression of Twist2 in liver, fat and adipocyte. (A) RT±PCR analysis of Twist2 mRNA expression in fat and liver tissue. (B) Semi-quantitative
RT±PCR analysis of Twist2 mRNA in 3T3-L1 preadipocytes (pre) and adipocytes (adipo). (C) Northern blot analysis of Twist2 mRNA during adipocyte
differentiation in 3T3-F442A. At the indicated time points, cells were harvested and total RNA isolated for northern blot analysis (see Materials and Methods
for details). The b-actin expression level was used to correct for differences in RNA loading. Asterisks denote non-speci®c PCR products. Arrowhead
indicates the Twist2 PCR product. Cycles for the PCR ampli®cations are 32 for Twist2, 23 for AdipoQ, 25 for PPARg, 22 for GAPDH and 28 for
ADD1/SREBP1c.
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both fat and liver tissues where ADD1/SREBP1c is highly
expressed (Fig. 2), and ectopic expression of Twist2 repressed
transcription by ADD1/SREBP1c at both FAS and ADD1/
SREBP1c promoters (Fig. 3). It is likely that repression by
Twist2 is due to inhibition of DNA binding, because over-
expression of Twist2 attenuated the DNA-binding ability of
ADD1/SREBP1c in vivo and in vitro (Figs 4 and 5).
Furthermore, HDAC inhibitors such as sodium butyrate
abolished Twist2-dependent repression, implying that the
transcriptional activity of ADD1/SREBP1c may be regulated
by Twist2 via HDACs.
These observations suggest that bHLH transcription factors,
which regulate cell type determination and differentiation by
Ids and/or Twists, act by a common mechanism. It has been
reported previously that the transcription by ADD1/SREBP1c,
like MyoD, is down-regulated by Ids (37). However, it is
likely that the mechanism by which Twist2 inhibits MyoD-
and ADD1/SREBP1c-dependent transcription are not identi-
cal. Twist2 inhibits MyoD indirectly by squelching E12
protein while Twist2 forms a protein complex with ADD1/
SREBP1c and interferes with the domains of ADD1/SREBP1c
necessary for transcriptional activation.
As described above, the N-terminal acidic domains of
SREBPs are important for their transcriptional activity by
associating with co-activators. The acidic domain (amino
acids 1±50) of SREBP1a interacts with the ARC (activator-
recruited cofactor) complex for transcriptional activation (17).
As shown here by yeast two-hybrid analysis, it is likely that
Figure 3. Suppression of the transcriptional activity of ADD1/SREBP1c by Twist2. (A±D) H293 cells were transfected with the FAS-promoter reporter gene
(A and D) or ADD1/SREBP1c-promoter reporter gene (B and C) along with pRSV-b-gal, ADD1/SREBP1c, Twist2 and/or other expression vectors, as
indicated. Empty expression plasmids were added to give identical amounts of DNA in the transfection assays. (C) LXRa-dependent activation of
ADD1/SREBP1c promoter is not in¯uenced by co-expression with Twist2. (D) Twist2 effect on the transcriptional activity of other SREBPs. Amount of
DNAs used in each well for the luciferase reporter assay is as follows: ADD1/SREBP1c (200 ng), Twist2 (used as indicated in the ®gure), LXRa/RXRa
(500 ng for each), SREBP1 (200 ng), SREBP2 (200 ng).
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ADD1/SREBP1c interacts with Twist2 through its short acidic
domain (amino acids 1±60), but not its other domains that
include the bHLH domain (amino acids 308±403). In addition,
Twist2 expression did affect the transcriptional activity of
SREBP1a, as well as ADD1/SREBP1c, but not SREBP2
(Fig. 3). The acidic region of SREBP1a includes almost all
amino acid sequences, which that of ADD1/SREBP1c have.
Thus, this result also supports that Twist2-mediated transcrip-
tional repression might be mediated by the interaction through
the N-terminal acidic region of ADD1/SREBP1c. Therefore,
we can exclude the possibility that the interaction between
Twist2 and ADD1/SREBP1c is via the HLH domain. Instead,
it appears that Twist2 binding to the N-terminal region of
ADD1/SREBP1c down-regulates transcription by ADD1/
SREBP1c either by squelching co-activator binding to
ADD1/SREBP1c, recruiting co-repressors to the acidic
domain, or changing the conformation of ADD1/SREBP1c
into an inactive form that cannot bind to DNA. On the basis of
our observations, the latter two models seem to be plausible
explanations of how Twist2 regulates the transcriptional
activity of ADD1/SREBP1c. As assessed by in vivo ChIP
assay and in vitro EMSA, the interaction between ADD1/
SREBP1c and Twist2 clearly reduced the DNA-binding
ability of ADD1/SREBP1c (Figs 4 and 5). A DNA±ADD1/
SREBP1c±Twist2 triple complex was not observed with
E-box or SRE probes in EMSA (Fig. 4). Instead, addition of
Figure 4. Inhibition of ADD1/SREBP1c DNA-binding by Twist2 in vitro. EMSAs were preformed with 32P-labeled ABS (E-Box) (A) and SRE (B) oligo-
nucleotide probes and in vitro translated ADD1/SREBP1c-Myc/His and/or Flag-Twist2 proteins. The speci®c probe±ADD1/SREBP1c complex was abolished
by addition of a 100-fold molar excess of unlabeled ABS or SRE-1 oligonucleotides (lane 4 of each panel), but not ARE7 (lane 5 of each panel). (A) The
speci®city of the probe±ADD1/SREBP1c complex con®rmed by supershift (lane 6). The amount of the ABS probe±ADD1/SREBP1c complex was decreased
by the addition of Twist2 (lanes 8 and 9), but not by mock protein (lanes 11 and 12). a-Flag antibody neutralized repression by Twist2 (lane10). (B) Addition
of Twist2 reduced the amount of the SRE probe±ADD1/SREBP1c complex (lane 7±9). Asterisks indicate non-speci®c binding to each probe by unprogrammed
lysate (mock protein). S.C, speci®c competition with cold SRE or E-box oligonucleotide; N.C, non-speci®c competition with ARE7 oligonucleotide probe.
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Twist2 reduced the amount of DNA-bound ADD1/SREBP1c
just like Ids. These results suggest that Twist2 binding to
ADD1/SREBP1c itself reduces the DNA-binding af®nity of
ADD1/SREBP1c, possibly by changing the conformation of
ADD1/SREBP1c into a transcriptionally inactive form.
Furthermore, as proposed by Gong et al. in the repression of
transcriptional activity of MyoD by Twist2, it is also likely
that Twist2-dependent transcriptional repression of ADD1/
SREBP1c is, at least partially, mediated by the formation of
transcriptionally inactive protein complex through recruiting
co-repressors to ADD1/SREBP1c target gene promoter region
(25). As described above, sodium butyrate, which is a well-
known HDAC inhibitor, relieved the Twist2-induced tran-
scriptional suppression of ADD1/SREBP1c, which implies
that Twist2 represses the transactivity of ADD1/SREBP1c by
recruiting HDACs. Although, the mechanism(s) by which
Twist2 recruits co-repressors to the ADD1/SREBP1c target
gene promoter region remains to be elucidated, it is plausible
that Twist2 recruiting co-repressors to ADD1/SREBP1c might
change protein complex or inactivate it by protein modi®ca-
tions. Recently, Giandomenico et al. reported that p300
binding to SREBP1a increases the DNA-binding ability of
SREBP1a, and p300-dependent acetylation of SREBP1a and
SREBP2 regulates their protein stability (38).
One may speculate that Twist2, as a repressor of ADD1/
SREBP1c, affects several aspects of energy homeostasis
regulated by ADD1/SREBP1c (39,40). For example, in-
creased production of TNFa is observed in the obese state
Figure 5. Inhibition of ADD1/SREBP1c DNA binding by Twist2 in vivo.
(A) ChIP analysis of Twist2-mediated repression of the DNA-binding
ability of ADD1/SREBP1c. H293 cells were transfected in duplicate (for
use in western blot analysis) with the DNAs indicated. After cross-linking
with formaldehyde, cells were lysed, pelleted and sonicated, and ADD1/
SREBP1c was immunoprecipitated with anti-Myc antibody. Complexes
were eluted, cross-linking was reversed and puri®ed DNA was used as a
template for PCR, using primers for the promoter region of ADD1/
SREBP1c containing a SRE site. [a-32P]dCTP-labeled PCR products were
resolved by non-denaturing PAGE, and analyzed using a phosphoimager.
(B) Western blot analysis of transfected proteins. Transfected cells were
lysed, harvested and total protein was resolved by SDS±PAGE and
evaluated using a-Myc and a-Flag antibodies to detect ADD1/SREBP1c
and Twist2, respectively. Asterisk denotes a non-speci®c protein band.
Figure 6. HDAC-dependent repression of the transcriptional activity of
ADD1/SREBP1c by Twist2. (A) and (B) H293 cells were transfected with
the indicated expression vectors in the presence of a FAS-luciferase reporter
gene. (A) Transfected cells were incubated overnight in DMEM medium
supplemented with 10% bovine calf serum and/or 5 and 50 mM of sodium
butyrate (NaBt) before harvesting for luciferase assay. (B) Co-transfection
of HDAC1 enhances the repressive effect of Twist2 on the transcriptional
activity of ADD1/SREBP1c. Amount of DNAs used in each well for the
luciferase reporter assay is as follows: ADD1/SREBP1c (200 ng), Twist2
(500 ng or as indicated in the ®gure), HDAC1 (200 ng).
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and has been implicated in obesity-associated insulin
resistance. Also, TNFa has been shown to block the
stimulatory effect of insulin on ADD1/SREBP1c in human
adipocytes (41). Thus, it is likely that this TNFa-induced
down-regulation of ADD1/SREBP1c in the adipocytes of
obese or diabetic patients is, at least partially, mediated by
increased levels of Twist2, because TNFa has been shown to
stimulate expression of Twists (26). Consistent with this, we
have observed elevated Twist protein levels in fat tissue from
ob/ob and db/db mice that have an obese phenotype combined
with severe insulin resistance and high serum TNFa (Y.S.Lee
and J.B.Kim, unpublished data).
In summary, we have shown that Twist2 is a novel ADD1/
SREBP1c interacting protein. Since the interaction between
ADD1/SREBP1c and Twist2 suppressed the transcriptional
activity of ADD1/SREBP1c, abnormal expression of Twist2
may affect energy homeostasis such as lipid and glucose
metabolism, which are governed by ADD1/SREBP1c.
However, future studies are required to de®ne the role of
Twist2 and ADD1/SREBP1c in whole body energy
homeostasis.
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